Skip to main content
SpringerLink
Log in

Medical management of obesity: present and future therapy

  • Published:
Journal of Gastrointestinal Surgery

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167–172.

    Article  PubMed  Google Scholar 

  2. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet 2000;356:2119–2125.

    Article  CAS  PubMed  Google Scholar 

  3. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med 2001;161:218–227.

    Article  CAS  PubMed  Google Scholar 

  4. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189–198.

    Article  CAS  PubMed  Google Scholar 

  5. National Institutes of Health, National Heart, Lung and Blood Institute, and North American Association for the Study of Obesity. Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; October 2000. NIH Publication No. 00-4084.

  6. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000;160:2185–2191.

    Article  CAS  PubMed  Google Scholar 

  7. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Prac 2001;50:505–512.

    CAS  Google Scholar 

  8. Wirth A, Krause J. Long-term weight loss with sibutramine. A randomized controlled trial. JAMA 2001;286:1331–1339.

    Article  CAS  PubMed  Google Scholar 

  9. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179–184.

    Article  CAS  PubMed  Google Scholar 

  10. Hadvary P, Lengsfield H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1998;256:357–361.

    Article  Google Scholar 

  11. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82–86.

    Article  CAS  PubMed  Google Scholar 

  12. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235–242.

    Article  CAS  PubMed  Google Scholar 

  13. Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8:49–61.

    Article  PubMed  Google Scholar 

  14. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306–313.

    Article  CAS  PubMed  Google Scholar 

  15. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160–167.

    Article  CAS  PubMed  Google Scholar 

  16. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288–1294.

    Article  CAS  PubMed  Google Scholar 

  17. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000;248:245–254.

    Article  CAS  PubMed  Google Scholar 

  18. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side-effects of orlistat by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001;25:1095–1099.

    Article  CAS  PubMed  Google Scholar 

  19. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12-S23.

    CAS  PubMed  Google Scholar 

  20. Colman E, Fossler M. Reduction in blood cyclosporin concentrations by orlistat. N Engl J Med 2000;342:1141–1142.

    Article  CAS  PubMed  Google Scholar 

  21. Schnetzler B, Kondo-Oestreicher M, Vala D. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000;70:1540–1541.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Human Nutrition, Washington University School of Medicine, 660 S. Euclid Ave., Box 8031, 63110-1093, St. Louis, MO

    Samuel Klein M.D.

Authors
  1. Samuel Klein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Klein M.D..

Additional information

Supported by grants DK 37948, DK 56341, and RR-00036 from the National Institutes of Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, S. Medical management of obesity: present and future therapy. J Gastrointest Surg 7, 464–467 (2003). https://doi.org/10.1016/S1091-255X(03)00049-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1091-255X(03)00049-0

Keywords

Search

Navigation